CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.
See the rest here:
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
Recommendation and review posted by Fredricko
